Holen Sie sich die Stockscreener-App
2.76
5.75%
0.15
Handel nachbörslich:
2.77
0.01
+0.36%
Schlusskurs vom Vortag:
$2.61
Offen:
$2.68
24-Stunden-Volumen:
6.38M
Relative Volume:
1.06
Marktkapitalisierung:
$944.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-7.8857
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
+17.95%
1M Leistung:
+28.97%
6M Leistung:
+21.59%
1J Leistung:
+0.73%
1-Tages-Spanne:
$2.59
$2.765
1-Wochen-Bereich:
$2.18
$2.765
52-Wochen-Spanne:
$1.54
$3.455
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.76 | 893.33M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Nuvation Bio's Breakthrough FDA-Approved Iprozy and Its Implications for Biotech Growth - AInvest
Transcript : Nuvation Bio Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Nuvation Bio’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Nuvation Bio (NUVB.N) Spikes 11.6% Intraday: A Deep Dive Into the Unusual Move - AInvest
Nuvation Bio (NUVB.N) Surges 12.5%—What’s Fueling the Move? - AInvest
Nuvation Bio Inc. (NYSE:NUVB) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - 富途牛牛
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates - MSN
Nuvation Bio shares rise 1.30% after-hours after RBC raised its price target to $7. - AInvest
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for IDH1 Mutant Glioma - TipRanks
RBC Raises Price Target on Nuvation Bio to $7 From $6, Keeps Outperform, Speculative Risk - MarketScreener
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Nuvation Bio Inc (NUVB) Q2 2025 Earnings Call Highlights: Strong IBTROZI Launch and Strategic ... By GuruFocus - Investing.com Canada
Nuvation Bio’s Milestone with FDA Approval of IBTROZI - TipRanks
NUVB Sales Jump 1,043% on Drug Launch - AOL.com
Nuvation Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Earnings call transcript: Nuvation Bio Q2 2025 sees steady EPS, stock rises - Investing.com
Nuvation Bio Inc. SEC 10-Q Report - TradingView
Nuvation Bio earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q2 Revenue $4.8M - MarketScreener
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses - BioSpace
Nuvation Bio Presents New IBTROZI Data at WCLC and ESMO Congresses - AInvest
What are the latest earnings results for Nuvation Bio Inc.Consistent triple-digit returns - Jammu Links News
What makes Nuvation Bio Inc. stock price move sharplyCapitalize on market trends with confidence - Jammu Links News
Nuvation Bio Inc. Stock Analysis and ForecastDiscover undervalued stocks before they soar - Jammu Links News
Nuvation Bio (NUVB.N) Plunges 5.5%: What’s Behind the Sudden Sell-Off? - AInvest
Nuvation Bio Announces Q2 2025 Financial Results and Business Update on August 7, 2025. - AInvest
What catalysts could drive Nuvation Bio Inc. stock higher in 2025Get real-time alerts on top-performing stocks - Jammu Links News
Nuvation Bio (NUVB.N) Drops 5.5%: What’s Behind the Sudden Slide? - AInvest
How does Nuvation Bio Inc. generate profit in a changing economyFree Investment Case Studies - Jammu Links News
How does Nuvation Bio Inc. compare to its industry peersFree Trend-Following Techniques - Jammu Links News
Is Nuvation Bio Inc. a good long term investmentExceptional financial outcomes - Jammu Links News
What institutional investors are buying Nuvation Bio Inc. stockConsistent wealth multiplication - Jammu Links News
Is Nuvation Bio Inc. a growth stock or a value stockInvest in stocks with long-term growth potential - Jammu Links News
RBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PT - MSN
What is the dividend policy of Nuvation Bio Inc. stockBreakout portfolio performance - Jammu Links News
What markets is GLXG expanding into Is Nuvation Bio Inc. stock a good long term investment optionUnlock powerful portfolio management tools - Jammu Links News
Quant Models Detect Momentum Reversal in Nuvation Bio Inc.AI Forecast for Trending Stocks Indicates Upside - beatles.ru
Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment - Insider Monkey
When is Nuvation Bio Inc. stock expected to show significant growthAdvanced Screener Guidance With High Returns - Jammu Links News
10 Penny Stocks That Will Skyrocket - Insider Monkey
Institutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year losses - Yahoo Finance
What institutional flow reveals about Nuvation Bio Inc.Earnings Play Trade Plan With Alerts Shared - metal.it
Analysts Boost Healthcare Stocks: Aclaris Therapeutics and Nuvation Bio - AInvest
Nuvation Bio Inc. Outperforms Peers on Volume MetricsProfit Focused Stock Screener Results Released - metal.it
Nuvation Bio (NUVB.N) Surges 8.6% — Unpacking the Intraday Spike Without Fundamentals - AInvest
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):